Wells Fargo dispatches biotech banker to Cambridge/Boston supercluster

With the Cambridge/Boston biotech supercluster forming a kind of global crossroads for drug development, bankers are going the extra mile to get in on the act. In Wells Fargo's case, it's going an extra 3,000 miles out of its way. Wells Fargo life sciences specialist Katherine Andersen is uprooting herself from Palo Alto, CA, to make the trek to Boston. "It's challenging to grow relationships from 3,000 miles away," Andersen told the Boston Globe. Story

Suggested Articles

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.

Aligos Therapeutics is shooting for a $100 million IPO to help drive its early work on a functional cure for chronic hepatitis B as well as COVID-19.